The Evidence Based Hair Podcast was created by dermatologist & hair loss specialist Dr Jeff Donovan to highlight new, hot off the press, world-class research in the field of hair loss. The podcast was created for hair loss practitioners around the world who care for patients with all different types of hair loss. Each week, different hair loss research topics are covered in the podcast including new research related to androgenetic alopecia, alopecia areatea, telogen effluvium, traction alopecia, tinea capitis, trichotillomania, chemotherapy induced hair loss, lichen planopilaris, frontal fibrosing alopecia, dissecting cellulitis, folliculitis decalvans, discoid lupus, central centrifugal cicatricial alopecia, erosive pustular dermatosis.... and a whole lot more.

Welcome back to another episode of the Evidence-Based Hair Podcast! In this episode, we delve into a fascinating study on the use of generic tofacitinib for treating alopecia areata.

This study, published in the Archives of Dermatologic Research, explores the effectiveness and safety of generic tofacitinib. With the recent availability of this cost-effective alternative in Canada, the study provides valuable insights into whether switching from brand name options (Xeljanz) is a viable choice for patients.

The retrospective study included 20 patients with advanced alopecia areata, and the results were promising. A significant number of patients experienced noticeable improvements in hair regrowth, with low incidence of side effects. This episode discusses the study's findings and the broader implications for treatment options in alopecia areata.

Join me as we explore how this study might change the landscape of hair loss treatment and what it means for patients and practitioners alike. Don't miss next week's episode, where we'll discuss the use of baricitinib in young children.



STUDY REFERENCED in THIS EPISODE

Jian J et al. Effectiveness and safety of generic tofacitinib in alopecia areata: is the generic a cost-effective option? A retrospective study. Arch Dermatol Res. 2024 May 11;316(5):154. doi: 10.1007/s00403-024-02879-4.